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Background: Appropriate outcome selection is essential if research is to guide decision-making and
inform policy. Systematic reviews of the clinical, cosmetic and patient-reported outcomes of reconstruc-
tive breast surgery, however, have demonstratedmarked heterogeneity, and results from individual studies
cannot be compared or combined. Use of a core outcome set may improve the situation. The BRAVO
study developed a core outcome set for reconstructive breast surgery.
Methods: A long list of outcomes identified from systematic reviews and stakeholder interviews was used
to inform a questionnaire survey. Key stakeholders defined as individuals involved in decision-making
for reconstructive breast surgery, including patients, breast and plastic surgeons, specialist nurses and
psychologists, were sampled purposively and sent the questionnaire (round 1). This asked them to rate the
importance of each outcome on a 9-point Likert scale from 1 (not important) to 9 (extremely important).
The proportion of respondents rating each item as very important (score 7–9) was calculated. This was
fed back to participants in a second questionnaire (round 2). Respondents were asked to reprioritize
outcomes based on the feedback received. Items considered very important after round 2 were discussed
at consensus meetings, where the core outcome set was agreed.
Results: A total of 148 items were combined into 34 domains within six categories. Some 303 participants
(51⋅4 per cent) (215 (49⋅5 per cent) of 434 patients; 88 (56⋅4 per cent) of 156 professionals) completed
and returned the round 1 questionnaire, and 259 (85⋅5 per cent) reprioritized outcomes in round 2.
Fifteen items were excluded based on questionnaire scores and 19 were carried forward to the consensus
meetings, where a core outcome set containing 11 key outcomes was agreed.
Conclusion: The BRAVO study has used robust consensus methodology to develop a core outcome set
for reconstructive breast surgery.Widespread adoption by the reconstructive community will improve the
quality of outcome assessment in effectiveness studies. Future work will evaluate how these key outcomes
should best be measured.
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Introduction
Breast cancer affects almost 50 000 women in the UK
each year1, up to 40 per cent of whom will require a
mastectomy2. For some, the loss of a breast can be devas-
tating and reconstructive breast surgery (RBS) is offered
to improve outcomes3.
Decision-making in RBS, however, can be difficult.
There are several procedures available, ranging in
complexity from expander/implant-based reconstruc-
tions to more challenging autologous procedures4,5.
Factors such as body habitus, co-morbidities and the
need for postoperative radiotherapy6 may influence the
choice of reconstructive method. However, the majority of
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Table 1 Summary of methods used to develop a core outcome set
Phase 1 Identification of all outcomes that may be measured following reconstructive breast surgery
Systematic literature searches to identify clinical outcomes, patient-reported and cosmetic outcomes
Qualitative interviews with patients and healthcare professionals regarding which outcomes they feel should be measured following
reconstructive breast surgery
This produces a list of all potential outcomes
The list is grouped into outcome domains to avoid repetition
The domains inform questionnaire items to use in phase 2
Phase 2 Prioritization of outcomes by key stakeholders – Delphi survey
Stakeholders are surveyed and asked to prioritize each outcome
Results of the survey are fed back to stakeholders in a second survey (Delphi methods) and they are asked to reprioritize each outcome
Data are analysed by the research group using predefined criteria to reduce the list of information
This produces two outcome lists (from patients and healthcare professionals) ready for phase 3
Phase 3 Consensus meetings are held separately with key stakeholder groups
The items are presented to each group and items are rated as, ‘in’, ‘out’ or ‘unsure’ during anonymized voting
Items rated as ‘unsure’ are discussed and more voting is undertaken
The process produces two sets (1 selected by patients, 1 by professionals). These are compared and combined into one outcome set
patients are technically suitable for a range of procedures.
Patients and surgeons therefore face challenging decisions
regarding the optimal type and timing of surgery.
The provision of high-quality data, ideally from well
designed, multicentre randomized clinical trials (RCTs)
and prospective studies is central to this process7,8. Sys-
tematic reviews summarizing the clinical9, cosmetic10
and patient-reported11,12 outcomes of RBS, however,
have demonstrated a paucity of well designed studies,
and an inconsistent approach to outcome assessment and
reporting in each of these areas. Cross-study comparison
and meta-analysis is therefore difficult and the need for
improvement in outcome reporting in RBS is increasingly
being recognized9,10,13.
The standardization of endpoints (core outcome sets)
for use in effectiveness studies is one way in which inap-
propriate and non-uniform outcome reporting may be
addressed14,15. A core outcome set is defined as an agreed
set of outcomes to be reported as a minimum in all
studies of a particular condition15,16. Uptake of a core
outcome set has the potential to reduce reporting bias,
create homogeneity in outcome reporting and improve
meta-analysis17–22. It is hypothesized that development of
a core outcome set may result in similar improvements in
the value of research in RBS23,24.
The aim of the BRAVO (Breast ReconstructionAndValid
Outcomes) study was to use a robust consensus process to
develop a core outcome set for effectiveness studies in RBS.
Methods
Development of the core outcome set involved three
phases: phase 1, development of a questionnaire with a
list of potential outcomes; phase 2, sequential surveys
with key stakeholders using Delphi methods to prioritize
outcomes; and phase 3, consensus meetings with patients
and professionals to agree the core outcome set (Table 1,
Fig. 1). Full ethical approval was obtained for the study
(REC-11/SW/0305).
Phase 1: questionnaire development
A long list of outcomes was generated from systematic
reviews of the clinical9, cosmetic10 and patient-reported12
outcomes of breast reconstruction, and semistructured
interviews with patients and professionals were under-
taken as part of the BRAVE (Breast Reconstruction And
Valid Evidence) study, which aimed to determine the
feasibility of clinical trials in breast reconstruction25–29.
The list was constructed by two independent researchers
extracting verbatim each of the outcomes reported in
papers included in the systematic reviews. They scru-
tinized the transcripts of 62 semistructured interviews
with patients (implant-based reconstruction, 11 patients;
latissimus dorsi flap reconstruction, 10; abdominal flap
reconstruction, 11) and professionals (oncoplastic breast
surgeons, 11; plastic surgeons, 11; clinical nurse special-
ists, 11; psychologists, 2) conducted within the BRAVE
study during which outcome selection for research studies
was discussed. Duplicate items were removed and the
outcomes categorized into domains by two independent
researchers using the qualitative technique of content
analysis30, and dual extraction and categorization of out-
comes with senior discussion if discrepancies occurred31.
A domain was defined as a broad class of outcome; for
example, the domain wound-related problems included
infection, wound dehiscence, skin necrosis and delayed
wound healing. Domains were further categorized into
overarching outcome themes or ‘categories’ using the same
methodology31; for example, systemic complications and
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Patient consensus
meeting n = 15
Professional consensus
meeting n = 23
Professional-specific core outcomes (2 items)
 Implant-related complications
 Flap-related complications
No items excluded (criteria not met)
Patient-specific core outcomes (3 items)
 Physical well-being
 Emotional well-being
 Self-esteem
P
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Questionnaire development
34 domains in 6 categories operationalized into
questionnaire items for use in Delphi survey
Items common to both core outcome sets (6 items)
 Major complications
 Normality
 Quality of life
 Unplanned surgery for any reason
 Donor-site problems/morbidity<
 Women’s cosmetic satisfaction
Delphi round 1
34 domains in 6 categories
prioritized by 303 stakeholders
Delphi round 2
34 domains in 6 categories
reprioritized by 259 stakeholders
19 items carried forward to
consensus meetings
Feedback from round 1
and reprioritization focusing
on most important outcomes
Identification of long list of potential outcomes
Systematic reviews and patient and healthcare
professional interviews (148 items identified)
15 items excluded
 Systemic complications
 Long-term wound complications
 Breast symptoms
 Arm and shoulder symptoms
 Implant symptoms
 Objective cosmetic outcome
 No. of procedures
 Fatigue
 Recovery time
 Duration of procedure
 Time to complete reconstruction
 Clothing issues
 Financial issues
 Economic issues
 Cosmetic outcome
  assessed by patient’s partner
Fig. 1 Summary of the development of a core outcome set for reconstructive breast surgery. *Donor-site symptoms and donor-site
complications were merged into one item
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wound-related problems were classified as early complica-
tions and the identified domains were operationalized into
a questionnaire item, which involved asking respondents
how important it was to measure each item in research
and audit studies in RBS. Each item was structured with
the medical terminology in bold italics followed by a lay
description, as in the example: ‘How important is it to
assess implant-related complications – implant-related
problems such as infection that would require the implant
to be removed?’. This allowed the questionnaire to be read
and understood by all stakeholders. Respondents were
asked to score the importance of evaluating each item
in effectiveness studies in RBS on a 9-point Likert scale
from 1 (not important) to 9 (extremely important). The
scoring system was selected after discussion with the study
statistician and experts in core outcome set development
to facilitate maximum discrimination between question-
naire items based on previous experience in this area, and
has been used widely in this field14,32. The questionnaire
was piloted with patients and professionals to check face
validity, understanding and acceptability.
Phase 2: Delphi consensus methods
Delphi survey methods, with anonymized feedback of
results, involving key stakeholders were used to develop the
core outcome set33.
Stakeholder selection
Key stakeholders were defined as individuals who may
be involved in decision-making for RBS and would have
an in-depth understanding of which outcomes should be
measured in research and audit studies in this area. These
were identified by the BRAVO Steering Group as patients,
breast and plastic surgeons, clinical nurse specialists and
psychologists. The steering group elected a priori to recruit
patients and professionals in a 2 : 1 ratio such that patients’
views were represented preferentially when the groups
were combined because RBS is a patient-selected optional
intervention.
Patients were purposively sampled from three centres
(Bristol, Liverpool and Glasgow). All women who had
undergone RBS using expander/implants, latissimus dorsi
or abdominal flaps as either immediate or delayed pro-
cedures, or who had undergone therapeutic mammo-
plasty, defined as reduction pattern wide local excision and
contralateral symmetrization, within 5 years of the start
of the study were eligible to participate. Maximum varia-
tion sampling34 with a sampling matrix was used to ensure
adequate inclusion of all identified groups with regard
to procedure type (implant, latissimus dorsi and abdom-
inal flaps, therapeutic mammoplasty), timing of surgery
(immediate, delayed), age at time of surgery (less than
45 years, 45–65 years, over 65 years), time since surgery
(less than 2 years, 2–4 years, more than 4 years) and treat-
ment centre, such that a complete breadth of perspectives
was included. Attention was also paid to demographic fac-
tors such as educational background, employment andmar-
ital status to ensure that no group was excluded35.
Professionals were recruited purposively from breast and
plastic surgical units across the UK. Maximum variation
sampling was used with regard to type of centre (teaching
hospital versus district general hospital), sex and duration
of practice to ensure a comprehensive representation of
views.A priori, the aimwas to recruit 200 patients, 30 breast
surgeons, 30 plastic surgeons, 30 clinical nurse specialists
and ten psychologists. This was detailed in the full protocol
written for this study, which is available from the author.
Delphi surveys
Potential patient participants from all three centres were
approached by post. Responders consenting to partic-
ipate were sent a questionnaire with a prepaid enve-
lope. Non-responders were sent a reminder 3weeks later.
Healthcare professionals (HCPs) at breast and plastic
surgery centres in the UK were identified from previous
research participation and recent publications. Each pro-
fessional was contacted by post with a study invitation letter
and questionnaire. Non-responders were sent a reminder
3weeks later. Batches of invitations were sent until the
desired sample size was achieved or until the sample pool
had been exhausted.
The first-round questionnaires were analysed by cal-
culating the proportions of participants rating each item
as very important (score 7, 8 or 9). All respondents were
sent a second-round questionnaire containing summary
round 1 scores for each item; all feedback was anonymous.
First-round non-responders were considered to have
declined study participation and were not contacted again.
In round 2, participants were asked to reprioritize the
outcomes based on feedback from round 1. Participants
were also asked to identify the seven outcomes of most
importance, those ‘core’ to measure in effectiveness studies
in RBS.
Phase 3: consensus meetings
Separate consensus meetings for key stakeholders were
held to prevent professionals dominating the meetings.
The patients’ meeting was held in Bristol in February
2014, and the professionals’ meeting in Liverpool in July
2014. All patients and professionals who had completed the
round 2 questionnaire were invited to attend the consen-
sus meetings. Travel expenses were offered to encourage
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participation, but no additional financial incentives were
provided. Attendees were selected purposively to ensure
that all key stakeholder groups were represented, using
similar maximum variation criteria to those described for
phase 2.
Eachmeetingwas led by an independent facilitator whose
role was to lead and promote the discussion and medi-
ate if necessary. The meetings included a summary of the
work to date, discussion, and anonymous electronic vot-
ing using TurningPoint software (Turning Technologies,
Youngstown, Ohio, USA) to determine consensus.
A list of the items retained after round 2 was sent to
all participants in advance of the meeting to enable them
to consider independently which items they felt should be
included in the core outcome set. Each item was presented
in the meeting and attendees were asked to vote anony-
mously on their importance on a scale of 1 (not impor-
tant) to 9 (extremely important). Items were classified as
definitely ‘in’, definitely ‘out’ or ‘unsure’ based on prede-
termined criteria. Items that were classified as unsure were
discussed among the group. A further round of anonymized
voting was conducted, whereby participants were asked to
rate the item as in or out based on the discussion. Discus-
sion and voting were undertaken iteratively until consensus
was achieved. Members were then asked to ratify the final
core outcome set. All items retained from both the patients’
and HCPs’ meetings were included in the final combined
core set.
Sample size
There are currently no guidelines for the numbers of
participants required to develop a core outcome set14.
Given the complexity of RBS, however, it was considered
that approximately 300 participants would be necessary to
ensure that all the relevant stakeholder groups were sam-
pled adequately. In addition, approximately 20 participants
were approached for each consensus meeting to facilitate
discussion while ensuring that all key stakeholder sub-
groups were represented.
Data analysis
Items were retained for round 2 if more than 50 per cent
of respondents in either the patient or the professional
group, or both groups combined, scored the item 7–9, and
less than 15 per cent of either group or both combined
scored the item as not important (score 1–3). The patient
and professional groups were analysed separately initially
and also together. The separate analysis ensured that out-
comes important to individual stakeholder groups were not
excluded from the analysis prematurely.
In round 2, participants received group feedback from
round 1 in the form of the percentage of respondents
rating each item as very important (score 7–9), in
addition to their own score for that item from round
1. It was hypothesized that the type of feedback received
would influence how items were prioritized in round 2.
The feedback was therefore provided from either the par-
ticipants’ group alone (patients or professionals) or both
groups separately (patients and professionals) via random
allocation to allow this to be explored. Full details of the
impact of different stakeholder feedback on responses in
round 2 will be reported separately.
Round 2 responses were analysed with more stringent
criteria. Items rated as very important (score 7–9) by at
least 70 per cent of respondents in either the patient or pro-
fessional group, or both groups combined, were retained
and carried forward for discussion at the phase 3 consensus
meetings. These cut-offs were selected for pragmatic rea-
sons as there is currently no consensus regarding cut-off
selection in Delphi studies14,36.
Before the consensus meetings, criteria for consensus
regarding item inclusion and exclusion were agreed. Items
scored as extremely important (score 8 or 9) by more than
70 per cent of participants and not important (score 1–3)
by less than 15 per cent were definitely included in the final
core outcome set. Items considered as extremely important
(8 or 9) by less than 30 per cent of participants were defi-
nitely excluded from the final set. Ratification was sought
for the items definitely included or excluded following the
initial vote, and items that were scored 8 or 9 by between 30
and 70 per cent of participants were discussed by the group
in an attempt to reach consensus. A second round of anony-
mous interactive voting followed the discussion to deter-
mine whether these remaining items should be included
or excluded from the final core outcome set based on the
predetermined criteria. If uncertainty remained after the
second vote, further discussion was facilitated to allow con-
sensus to emerge. The consensus meetings concluded with
all participants ratifying the core outcome set for RBS.
Results
Phase 1: questionnaire development
Review of all data sources identified 148 individual out-
comes that were categorized using content analysis into
34 domains. These were further classified using the same
methodology into six categories: short and long-term com-
plications, symptoms, psychosocial well-being, practical
issues and cosmesis. Each domain was operationalized to
generate a questionnaire item (Table S1 and Appendix S1,
supporting information).
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Table 2 Demographics of participants in the BRAVO study
Round 1 Round 2 Consensus meetings
Patient participants n=215 n=190 n=15
Centre
Bristol 77 (35⋅8) 68 (35⋅8) 13 (87)
Liverpool 74 (34⋅4) 62 (32⋅6) 2 (13)
Glasgow 64 (29⋅8) 60 (31⋅6) 0 (0)
Age (years)*
<45 21 (9⋅8) 20 (10⋅5) 2 (13)
45–65 166 (77⋅2) 146 (76⋅8) 9 (60)
>65 28 (13⋅0) 24 (12⋅6) 4 (27)
Median (range) 54 (29–76) 54 (29–76) 55 (43–76)
Time since breast reconstruction (months)†
0–24 72 (33⋅5) 67 (35⋅3) 4 (27)
25–48 88 (40⋅9) 75 (39⋅5) 10 (67)
>48 49 (22⋅8) 42 (22⋅1) 1 (7)
Unknown 6 (2⋅8) 6 (3⋅2) 0 (0)
Median (range) 33 (4–97) 32 (4–97) 35 (21–72)
Timing of surgery
Immediate reconstruction 110 (51⋅2) 100 (52⋅6) 10 (67)
Delayed reconstruction 80 (37⋅2) 66 (34⋅7) 4 (27)
Therapeutic mammoplasty 25 (11⋅6) 24 (12⋅6) 1 (7)
Type of surgery
Implant-based reconstruction 54 (25⋅1) 47 (24⋅7) 4 (27)
Latissimus dorsi flap 59 (27⋅4) 52 (27⋅4) 5 (33)
Abdominal flap 74 (34⋅4) 64 (33⋅7) 5 (33)
Therapeutic mammoplasty 25 (11⋅6) 24 (12⋅6) 1 (7)
Other‡ 3 (1⋅4) 3 (1⋅6) 0 (0)
Education
Compulsory only 65 (30⋅2) 57 (30⋅0) 3 (20)
Additional education 139 (64⋅7) 125 (65⋅8) 11 (73)
Unknown 11 (5⋅1) 8 (4⋅2) 1 (7)
Marital status
Single 23 (10⋅7) 18 (9⋅5) 0 (0)
Married/living with partner 153 (71⋅2) 138 (72⋅6) 13 (87)
Separated or divorced 28 (13⋅0) 26 (13⋅7) 2 (13)
Widowed 6 (2⋅8) 4 (2⋅1) 0 (0)
Unknown 5 (2⋅3) 4 (2⋅1) 0 (0)
Employment status
Full- or part-time employment 130 (60⋅5) 118 (62⋅1) 11 (73)
Homemaker/housewife 17 (7⋅9) 11 (5⋅8) 0 (0)
Retired 45 (20⋅9) 42 (22⋅1) 3 (20)
Not working 16 (7⋅4) 13 (6⋅8) 0 (0)
Unknown 7 (3⋅3) 6 (3⋅2) 1 (7)
Professional participants n=88 n=69 n=23
Sex
F 46 (52) 37 (53⋅6) 14 (61)
M 42 (48) 32 (46⋅4) 9 (39)
Profession
Consultant breast surgeon 40 (45) 35 (51) 11 (48)
Consultant plastic surgeon 21 (24) 15 (22) 5 (22)
Clinical nurse specialist 20 (23) 15 (22) 6 (26)
Psychologist 7 (8) 4 (6) 1 (4)
Time in post (years)
<5 18 (20) 12 (17) 4 (17)
5–10 30 (34) 24 (35) 9 (39)
10–20 29 (33) 25 (36) 9 (39)
>20 8 (9) 6 (9) 0 (0)
Unknown 3 (3) 2 (3) 1 (4)
Values in parentheses are percentages unless indicated otherwise. *At time of breast reconstruction. †At time of entering study. ‡Patients undergoing
bilateral complex surgery who could not be classified into any one group.
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Table 3 Summary of item scores by round and outcome of consensus meetings by item
% rating item ‘very important’ (score 7–9)
Consensus meetings
(item voted ‘in’,
‘out’ or ‘unsure’)
Round 1 Round 2
Patients
(n=215)
HCPs
(n=88)
All
(n=303)
Patients
(n=190)
HCPs
(n=69)
All
(n=259)
Item carried
forward
to meeting
Patient/
HCP initial
views
Patient/
HCP final
decision
Problems that may occur in the first month
after operation
Systemic complications 71⋅6 60 68⋅3 54⋅4 41 50⋅8 No – –
Bleeding-related complications 83⋅3 59 76⋅2 74⋅9 43 66⋅3 Yes* Out/out Out/out
Wound-related complications 85⋅1 71 80⋅9 79⋅6 68 76⋅4 Yes* Out/out Out/out
Implant-related complications 87⋅7 92 89⋅0 83⋅8 90 85⋅4 Yes Out/in Out/in
Flap-related complications 89⋅7 92 90⋅4 87⋅0 91 88⋅2 Yes Unsure/unsure Out/in
Major complications 92⋅1 90 91⋅4 93⋅6 90 92⋅6 Yes In/in In/in
Problems that may occur in the months or years
after operation
Long-term wound-related complications 69⋅8 59 66⋅7 59⋅6 44 55⋅5 No – –
Long-term implant-related complications 83⋅0 82 82⋅7 77⋅7 77 77⋅3 Yes Unsure/unsure Out/out
Long-term flap-related complications 81⋅3 82 81⋅5 77⋅3 78 77⋅3 Yes Unsure/out Out/out
Donor-site complications 82⋅2 83 82⋅4 76⋅7 78 77⋅0 Yes Unsure/unsure In/in†
Unplanned surgery for any reason 83⋅7 84 83⋅8 82⋅1 83 82⋅2 Yes Unsure/unsure In/in
Symptoms that may occur after reconstructive
breast surgery
Fatigue 42⋅8 28 38⋅6 28⋅7 12 24⋅2 No – –
Breast symptoms 75⋅4 61 71⋅3 62⋅4 38 56⋅0 No – –
Arm and shoulder symptoms 73⋅5 78 74⋅9 67⋅7 57 65⋅0 No – –
Implant-related symptoms 72⋅5 71 71⋅9 62⋅4 59 61⋅4 No – –
Donor-site symptoms 79⋅3 73 77⋅4 72⋅5 65 70⋅4 Yes* Unsure/unsure In/in†
Self-esteem 81⋅4 88 83⋅2 83⋅5 87 84⋅4 Yes Unsure/unsure In/out
Body image 84⋅7 90 86⋅1 85⋅6 91 87⋅1 Yes Unsure/unsure Out/out
Normality 86⋅1 86 86⋅1 89⋅4 90 89⋅5 Yes In/in In/in
Emotional well-being 83⋅7 88 84⋅8 87⋅8 84 86⋅8 Yes Unsure/unsure In/out
Sexual well-being 77⋅9 80 78⋅4 72⋅0 77 73⋅5 Yes Out/out Out/out
Quality of life 87⋅4 98 90⋅4 92⋅5 97 93⋅7 Yes In/in In/in
Practical issues relating to reconstructive
breast surgery
Physical well-being 80⋅5 86 82⋅1 83⋅6 88 84⋅9 Yes In/unsure In/out
Recovery time 73⋅5 62 70⋅2 66⋅0 43 59⋅8 No – –
Duration of the procedure 48⋅6 32 43⋅8 28⋅0 13 24⋅2 No – –
Time to complete reconstruction 66⋅7 49 61⋅5 47⋅3 24 41⋅2 No – –
No. of procedures required 75⋅9 61 71⋅7 69⋅0 48 63⋅4 No – –
Clothing issues 65⋅9 76 68⋅9 66⋅1 63 65⋅2 No – –
Financial issues 54⋅2 51 53⋅3 39⋅2 30 36⋅7 No – –
Economic issues 35⋅1 60 42⋅4 23⋅9 39 27⋅8 No – –
Issues relating to the appearance of the
reconstructed breast
Patient-reported cosmetic outcome 91⋅6 93 92⋅1 94⋅7 97 95⋅3 Yes Unsure/unsure Out/out
Objective cosmetic outcome 76⋅2 72 74⋅8 68⋅6 63 67⋅2 No – –
Cosmetic appearance assessed by patient’s partner 56⋅3 55 56⋅0 51⋅4 37 47⋅4 No – –
Women’s cosmetic satisfaction 92⋅6 97 93⋅7 92⋅6 99 94⋅2 Yes In/in In/in
*Carried forward to meeting on basis of patient scores. †Items combined in final core outcome set. HCP, healthcare professional.
Phase 2: Delphi consensus methods
A total of 434 patients from three high-volume breast
units were invited to participate in round 1. Of these,
281 (64⋅7 per cent) responded; 39 (9⋅0 per cent) declined.
Of 242 (55⋅8 per cent) who consented to participate, 215
(88⋅8 per cent) completed and returned the questionnaire.
Participants had a median age of 54 (range 29–76) years
and had undergone the full range of reconstructive tech-
niques (expander/implants 54, 25⋅1 per cent; latissimus
dorsi flaps 59, 27⋅4 per cent; abdominal flaps 74, 34⋅4 per
cent) and therapeutic mammoplasty (25, 11⋅6 per cent).
These were carried out as immediate (110, 51⋅2 per cent)
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Table 4 Final core outcome set for effectiveness studies in reconstructive breast surgery
Item Definition (from questionnaire)
Implant-related complications* Implant-related problems in the first 30 days following surgery such as implant infection that would require
the implant to be removed
Flap-related complications* Problems with the tissue flap used to reconstruct the breast that occur within the first 30 days following
surgery including the need for another operation
Major complications† Any problem that leads to another operation or readmission to hospital for treatment after being sent home
in the first 30 days following the surgery
Unplanned surgery for any reason† Any problem that occurs in the months or years after breast reconstruction that requires an operation that is
not planned
Donor-site problems/morbidity† Any problems or symptoms arising from the area from which the tissue was taken to reconstruct the breast,
including hernias, stiffness or numbness in the back, tummy or bottom
Self-esteem‡ Feeling self-confident
Emotional well-being‡ Feelings of emotional and psychological health after surgery
Normality† Feeling ‘back to normal self’ or ‘whole’ as a result of surgery
Quality of life† Women’s quality of life following surgery
Physical well-being‡ Physical activity such as how well women can perform work and leisure-related tasks after surgery
Women’s cosmetic satisfaction† Women’s overall satisfaction with the appearance of their reconstructed breast(s) after surgery
*Item core to professional group only; †item core to both patients and professionals; ‡item core to patient group only.
and delayed (80, 37⋅2 per cent) procedures at a median of
33 (range 4–97) months before the study (Table 2).
Some 156 professionals were invited to participate, of
whom 88 (56⋅4 per cent) completed and returned the ques-
tionnaire. Respondents included 40 (45 per cent) breast
surgeons, 21 (24 per cent) plastic surgeons, 20 (23 per cent)
specialist nurses and seven (8 per cent) psychologists. No
professional actively declined to participate in the study
(Table 2).
In round 1, none of the items met the exclusion criteria,
so all 34 items were carried forward to round 2.
All round 1 respondents were invited to participate
in round 2. Of these, 259 (190 patients, 88⋅4 per cent;
69 HCPs, 78 per cent) completed and returned the
questionnaire. Demographics of patient and professional
participants were similar between rounds 1 and 2 (Table 2).
Round 1 scores were also similar between responders and
non-responders to round 2 scores for both stakeholder
groups (data not shown).
Provision of feedback, advice regarding reprioritiza-
tion of the most important items and application of the
more stringent cut-off criteria resulted in the exclusion
of 15 items following round 2 (Fig. 1). Nineteen items
were carried forward for discussion in the phase 3 con-
sensus meetings. These included three items (bleeding,
wound-related complications and donor-site symptoms)
that were excluded by the professional group, but retained
on the basis of patients’ views. Scores for individual items
in each round are shown in Table 3.
Phase 3: consensus meetings
Of the 190 patients invited, 16 agreed to participate in
the consensus meetings, and 15 who were representative
of the patient stakeholder group attended the meetings
(Table 2). Following the initial vote, five items (major com-
plications, normality, quality of life, physical well-being
andwomen’s cosmetic satisfaction) were definitely included
in the core outcome set and four items were definitely
excluded (Table 3). The remaining ten items were discussed
and revoted on. This led to four further items (unplanned
surgery, emotional well-being, self-esteem, and a com-
posite of donor-site complications and symptoms termed
‘problems’) being included in the final core outcome set
and five items being excluded. All group members ratified
the nine-item core outcome set.
Of the 69 professionals invited, 25 agreed to participate in
the consensus meeting and 23 who were representative of
the professional stakeholder group attended the meetings
(Table 2). Following the first vote, five items (major com-
plications, implant-related complications, quality of life,
normality and women’s cosmetic satisfaction) were defi-
nitely included and four items definitely excluded from
the core outcome set based on the prespecified criteria
(Table 3). The remaining ten items were discussed and
revoted on. This led to three further items (flap-related
complications, unplanned surgery, and a composite of
donor-site symptoms and complications) being included in
the core outcome set and the remaining six being excluded.
All members of the professional group then ratified the
eight-item core outcome set.
Combining the patient and professional sets generated a
final 11-item core outcome set (Fig. 1, Table 4).
Discussion
The BRAVO study has used rigorous consensus methods
involving key stakeholders to develop a core outcome
set for use in effectiveness studies in RBS. Effectiveness
studies are important to both patients and healthcare
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providers as they determine whether interventions work
in the real world, and therefore inform both clinical
decision-making and health policy37. The core outcome
set was developed following detailed scrutiny of the litera-
ture and qualitative work with patients and professionals to
identify all potentially relevant outcomes, followed by an
iterative consensus process using the views of over 250 key
stakeholders representative of women undergoing RBS
and professionals involved in the provision of specialist
care. The final core outcome set therefore includes 11
items that are important to both patients and profession-
als, such as major complications requiring readmission or
reoperation, unplanned surgery, quality of life, normal-
ity, self-esteem, physical and emotional well-being, and
women’s satisfaction with the cosmetic outcome of their
surgery. It is now recommended that researchers use the
core outcome set to inform the selection of measures used
in future effectiveness studies in RBS.
The concept of standardizing outcomes to reduce the
use of inappropriate outcomes, eliminate reporting bias
and facilitate data synthesis is not new. The OMER-
ACT (Outcome Measures in Rheumatoid Arthritis Clin-
ical Trials) initiative championed the methodology by des-
cribing a ‘filter’ of ‘truth, discrimination and feasibility’ to
determine outcome selection in rheumatoid arthritis over
20 years ago38,39, but it is only recently that the potential
for core outcome sets to improve the value of research
has been realized in a broader context21,40–44. To this
end, the UK Medical Research Council-funded COMET
(Core OutcomeMeasures in Effectiveness Trials) Initiative
(www.comet-initiative.org) was launched in January 2010,
with the ultimate aim of developing core outcome sets for
all conditions and treatments16. COMET aims to support
the development of core outcome sets by bringing together
researchers with an interest in the development, report-
ing and application of core outcome sets, with a view to
establishing robust and efficient methods by which new
sets may be developed16. COMET provides a means of
identifying existing, ongoing and planned core outcome
sets, and provides a free, publicly available internet-based
resource containing over 306 studies relevant to the devel-
opment of core outcome sets to facilitate the exchange of
ideas and information35,45. Over 300 core outcome sets are
currently under development, and standardized endpoints
have already been proposed for use in adjuvant breast can-
cer treatment trials46.
Although this work is novel and was conducted using
robust consensus methodology with key stakeholders who
were representative of women undergoing reconstructive
surgery and the professionals involved in the provision of
specialist care, there are some methodological limitations.
There is no agreement regarding the optimal methodol-
ogy for the development of a core outcome set and it is
possible that an alternative consensus method may have
led to a different final set of items. However, given the
scope and setting of this core outcome set, the Delphi
process and consensus meetings were considered appro-
priate and enabled a much larger sample of participants
to be involved than other purely face-to-face methods
would have allowed. The response rate in round 1 was
only 51⋅4 per cent, suggesting that the use of question-
naires and consensus meetings may not have appealed to
all stakeholders. Non-responders may have valued differ-
ent outcomes to the participants. Data were not collected
on these individuals as they did not give consent to partici-
pate, so variations between responders and non-responders
could not be explored fully. The use of a robust maximum
variation sampling strategy, however, ensured that all pre-
defined stakeholder subgroups were sampled adequately
such that the sample was as representative as possible of
the women undergoing reconstructive surgery and pro-
fessionals involved in their care. It was therefore unlikely
that any major group was not represented. It is also pos-
sible that the composition of the stakeholder groups may
have influenced the outcomes selected for inclusion in the
final core outcome set. Although early subgroup analysis
suggested that different specialties may initially prioritize
different outcomes, as the study progressed there was less
heterogeneity in the outcomes selected. This convergence
of views is likely to represent the fact that the selected
items in a core outcome set are only the baseline mini-
mum number to include in all studies, and the stakeholders
appreciated that future studies in their particular field could
result in the inclusion of additional and specific items as
required.
The main limitation of the study is that it was conducted
solely within the UK, which has a state-funded healthcare
system. It is unclear to what degree the outcomes valued in
this setting would be concordant with those valued in other
healthcare systems or cultural settings. This may limit the
generalizability of the results. Finally, the core outcome
set was developed specifically for RBS without reference
to breast cancer or its treatment. As many women undergo
RBS following a diagnosis of malignancy, there may be a
need to develop and integrate a breast cancer surgery core
outcome set to ensure that outcomes that are important in
this context are included.
This work has identified a list of core outcome domains
to be measured and reported as a minimum in effective-
ness studies in RBS. As a core outcome set is not itself a
measurement instrument, the next crucial step will be to
determine how these key outcomes should be measured;
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the recently published OMERACT Filter 2.039 provides
guidance in this area. Literature reviews will be required
to generate a list of available measurement instruments
and, where no instruments are available, these will need to
be developed. Application of further consensus methods
will therefore be necessary to determine what constitutes
major, implant-related and flap-related complications, and
how these should be defined. In addition, the development
of a robust instrument to evaluate domains such as nor-
mality will be vital if the core outcome set is to be applied
in a meaningful way. Application of the principles of truth,
discrimination and feasibility39 or, more formally, the
COSMIN (COnsensus-based Standards for the selection
of health Measurement INstruments) checklist47 may help
to inform the selection of the most appropriate instrument
for domains such as physical well-being and health-related
quality of life where more than one instrument could be
used. This additional work will be essential for the core
outcome set in RBS to gain widespread acceptance and use.
The BRAVO study has used robust consensus methodol-
ogy to develop a core outcome set for effectiveness stud-
ies in RBS. Its widespread adoption by the reconstructive
community will improve the quality of outcome assessment
and the value of the work to patients and surgeons. Future
work will be necessary to evaluate how these key outcomes
should best be assessed.
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